Add time:08/17/2019         Source:sciencedirect.com

BackgroundEmesis and nausea are common adverse effects of chemotherapy. Consequences include dehydration, acute renal failure, esophageal rupture, electrolyte imbalance and undernutrition, among others. First-generation 5-HT3 antagonists significantly reduce these symptoms but are expensive and require administration every 8–12 h. Palonosetron, a second generation 5-HT3 antagonist has proven better results in adult populations. Other benefits include a one-dose administration with effect for up to 7 days and a lower treatment cost. No clinical studies have evaluated the safety and efficacy of palonosetron in children.

We also recommend Trading Suppliers and Manufacturers of PALONOSETRON HCL (cas 135729-75-8). Pls Click Website Link as below: cas 135729-75-8 suppliers